, Volume 17, Issue 5, pp 573–582 | Cite as

Selective inhibition of group II phospholipase A2 by quercetin

  • Mats Lindahl
  • Christer Tagesson
Original Articles


The influence of quercetin, chlorpromazine, aristolochic acid, and indomethacin on group I phospholipase A2 (PLA2) from porcine pancreas and on group II PLA2 fromVipera russelli was compared. Quercetin and chlorpromazine were found to inhibit PLA2 activity in lower concentrations (< 100μM), while aristolochic acid and indomethacin were inhibitory only in higher concentrations (> 100μM). The order of potency againstVipera PLA2 was: quercetin >chlorpromazin aristolochic acid > indomethacin, while the order of potency against pancreatic PLA2 was: chlorpromazine > aristolochic acid > indomethacin> quercetin. Thus, quercetin was a potent inhibitor towards group II PLA2 (IC50=2μM), but a very weak inhibitor against group I PLA2, with maximum 30% inhibition. Aristolochic acid and indomethacin were three to four times more potent towards group II PLA2 than towards group I PLA2, while chlorpromazine was equally potent towards the two PLA2 types. Quercetin and chlorpromazine were also tested against two PLA2 fractions purified from the plasma of septic shock patients; chlorpromazine was then equally potent towards the two PLA2 fractions, whereas quercetin was a potent inhibitor of only one of the two PLA2 fractions (IC50=4μM). Together, these results indicate that (1) different PLA2 inhibitors have different potency depending on which type of PLA2 they are used against, (2) quercetin selectively inhibits group II PLA2 and may therefore be used to discriminate between different PLA2 forms in biological materials, and (3) both PLA2 of group I and group II are present in septic shock plasma.


Septic Shock Quercetin Indomethacin Potent Inhibitor Selective Inhibition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chang, J., J. H. Musser, andH. McGregor. 1987. Phospholipase A2: Function and pharmacological regulation.Biochem. Pharmacol. 36:2429–2436.Google Scholar
  2. 2.
    Pruzanski, W., E. C. Keystone, B. Sternby, C. Bombardier, K. M. Snow, andP. Vadas. 1988. Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis.J. Rheumatol. 15:1351–1355.Google Scholar
  3. 3.
    Vadas, P., W. Pruzanski, andE. Stefanski. 1988. Extracellular phospholipase A2: Causative agent in circulatory collapse of septic shock?Agents Actions 24:320–325.Google Scholar
  4. 4.
    Crowl, R. M., T. J. Stoller, R. R. Conroy, andC. R. Stoner. 1991. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response.J. Biol. Chem. 266:2647–2651.Google Scholar
  5. 5.
    Pruzanski, W., andP. Vadas. 1991. Phospholipase A2-a mediator between proximal and distal effectors of inflammation.Immunol. Today 12:143–146.Google Scholar
  6. 6.
    Davidson, F. F., andE. A. Dennis. 1990. Evolutionary relationships and implications for the regulation of phospholipase A2 from venom to human secreted forms.J. Mol. Evol. 31:228–238.Google Scholar
  7. 7.
    Kramer, R. M., C. Hession, B. Johansen, G. Hayes, P. McGray, E. P. Chow, R. T. Tizard, andR, B. Pepinsky. 1989. Structure and properties of a human nonpancreatic phospholipase A2.J. Biol. Chem. 264:5768–5774.Google Scholar
  8. 8.
    Ono, T., H. Tojo, S. Kuramitsu, H. Kagamiyama, andM. Okamoto. 1988. Purification and characterization of a membrane-associated phospholipase A2 from rat spleen. Its comparison with a cytosolic phospholipase A2 S-1.J. Biol. Chem. 263:5732–5738.Google Scholar
  9. 9.
    Nakano, T., andH. Arita. 1990. Enhanced expression of group II phospholipase A2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoid.FEBS Lett. 273:23–26.Google Scholar
  10. 10.
    Matsuda, Y., M. Ogawa, T. Shibata, K. Nakaguchi, J.-I. Nishijima, C. Wakasugi, andT. Mori. 1987. Distribution of immunoreactive pancreatic phospholipase A2 (IPPL-2) in various human tissues.Res. Commun. Chem. Pathol. Pharmacol. 58:281–284.Google Scholar
  11. 11.
    Wright, G. W., C. E. Ooi, J. Weiss, andP. Elsbach. 1990. Purification of a cellular (granulocyte) and extracellular (serum) phospholipase A2 that participate in the destruction ofEscherichia coli in a rabbit inflammatory exudate.J. Biol. Chem. 265:6675–6681.Google Scholar
  12. 12.
    Minami, T., H. Tojo, Y. Shinomura, S. Tarui, andM. Okamoto. 1992. Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: Its correlation with disease activity of Crohn's disease and ulcerative colitis.Gut 33:914–921.Google Scholar
  13. 13.
    Vadas, P., K. Scott, G. Smith, I. Rajkovic, E. Stefanski, B. D. Schouten, R. Singh, andW. Pruzanski. 1992. Serum phospholipase A2 enzyme activity and immunoreactivity in a prospective analysis of patients with septic shock.Life Sci. 50:807–811.Google Scholar
  14. 14.
    Kitigawa, M., T. Hayakawa, T. Kondo, T. Shibata, Y. Sakai, H. Sobajima, H. Ishiguro, M. Tanikawa, Y. Nakae, S. Kameya, andA. Noda. 1991. Elevation of serum phospholipase A2 in patients at an intensive care unit.Int. J. Pancreatol. 10:279–286.Google Scholar
  15. 15.
    Marshall, L. A., J. Bauer, M. L. Sung, andJ. Y. Chang. 1991. Evaluation of antirheumatic drugs for their effect in vitro on purified human synovial fluid phospholipase A2.J. Rheumatol. 18:59–65.Google Scholar
  16. 16.
    Mobilio, D., andL. A. Marshall. 1989. Recent advances in the design and evaluation of inhibitors of phospholipase A2.Annu. Rep. Med. Chem. 24:157–166.Google Scholar
  17. 17.
    Patriarca, P., S. Beckerdite, andP. Elsbach. 1972. Phospholipase and phospholipid turnover inEscherichia coli spheroplasts.Biochim. Biophys. Acta 260:593–600.Google Scholar
  18. 18.
    Lindahl, M., C. de Wit, B. Weström, H. von Schenck, andC. Tagesson. 1991. Demonstration of a phospholipase A2 inhibitor in human plasma and in plasma from the european hedgehog (Erinaceus europaeus).Int. J. Biochem. 23:287–292.Google Scholar
  19. 19.
    Vadas, P., E. Stefanski, andW. Pruzanski. 1986. Potential therapeutic efficacy of inhibitors of human phospholipase A2 in septic shock.Agents Actions 19:194–202.Google Scholar
  20. 20.
    Lindahl, M., H. von Schenck, andC. Tagesson. 1989. Isolation and characterization of phospholipase A2 from rat lung with affinity chromatography and two-dimensional gel electrophoresis.Biochim. Biophys. Acta 1005:282–288.Google Scholar
  21. 21.
    Nicholson, D. P. 1983. Corticosteroids in treatment of septic shock and the adult respiratory distress syndrome.Med. Clin. North Am. 67:717–724.Google Scholar
  22. 22.
    Chang, J., M. D. Skowronek, M. L. Cherney, andA. J. Lewis. 1984. Differential effects of putative lipoxygenase inhibitors on arachidonic acid metabolism in cell-free and intact cell preparations.Inflammation 8:143–155.Google Scholar
  23. 23.
    Vishwanath, B. S., R. M. Kini, andT. V. Gowda. 1987. Characterization of three edemainducing phospholipase A2 enzymes from habu (Trimeresurus flavoviridis) venom and their interaction with the alkaloid aristolochic acid.Toxicon 25:501–515.Google Scholar
  24. 24.
    Vishwanath, B. S., A. G. A. Rao, andT. V. Gowda. 1987. Interaction of phospholipase A2 fromVipera russelli venom with aristolochic acid: A circular dichroism study.Toxicon 25:939–946.Google Scholar
  25. 25.
    Rosenthal, M. D., B. S. Vishwanath, andR. C. Franson. 1989. Effects of aristolochic acid on phospholipase A2 activity and arachidonate metabolism of human neutrophils.Biochim. Biophys. Acta 1001:1–8.Google Scholar
  26. 26.
    Waite, M. 1987. Pancreatic and snake venom phospholipases A2.In The Phospholipases. Handbook of Lipid ReseArch. Vol. 5. D. J. Hanahan, editor. Plenum Press, New York. 155–190.Google Scholar
  27. 27.
    Lindahl, M. 1990. Phospholipase A2 activation and inflammatory reactions in the lung. Linköping University Medical Dissertations No. 323, Linköping, Sweden.Google Scholar
  28. 28.
    Calhoun, W., J. Yu, A. Sung, T. T. Chau, L. A. Marshall, B. M. Weichman, andR. P. Carlson. 1989. Pharmacologic modulation of D-49 phospholipase A2-induced paw edema in the mouse.Agents Actions 27:418–421.Google Scholar
  29. 29.
    Lanni, C., andE. L. Becker. 1985. Inhibition of neutrophil phospholipase A2 by p-bromophenacyl bromide, nordihydroguaiaretic acid, 5,8,11,14-eicostetetrayenoic acid and quercetin.Int. Arch. Allergy. Appl. Immun. 76:214–217.Google Scholar
  30. 30.
    Fawzy, A. A., B. S. Vishwanath, andR. C. Franson. 1988. Inhibition of human nonpancreatic phospholipase A2 by retinoids and flavonoids. Mechanism of action.Agents Actions 25:394–400.Google Scholar
  31. 31.
    Baur, M., T. O. Schmid, andB. Landauer. 1989. Role of phospholipase A in multiorgan failure with special reference to ARDS and acute renal failure (ARF).Klin. Wochenschr. 67:196–202.Google Scholar
  32. 32.
    Hoffmann, G. E., andW. G. Guder. 1989. Serum phospholipase-regulatory and pathophysiological aspects.Klin. Wochenschr. 67:144–148.Google Scholar
  33. 33.
    Vadas, P., W. Pruzanski, E. Stefanski, andB. Sternby. 1990. Compartmental heterogeneity of soluble phospholipase A.Inflammation 14:173–183.Google Scholar
  34. 34.
    Eskola, J. U., T. J. Nevalainen, andP. Kortesuo. 1988. Immunoreactive pancreatic phospholipase A2 and catalytically active phospholipase A2 in serum from patients with acute pancreatitis.Clin. Chem. 34:1052–1054.Google Scholar
  35. 35.
    Pruzanski, W., S. Saito, E. Stefanski, andP. Vadas. 1991. Comparison of group I and II soluble phospholipase A2 activities on phagocytic functions of human polymorphonuclear and mononuclear phagocytes.Inflammation 15:127–135.Google Scholar
  36. 36.
    Hanasaki, K., andH. Arita. 1992. Characterization of a high affinity binding site for pancreatic-type phospholipase A2 in the rat. Its cellular and tissue distribution.J. Biol. Chem. 267:6414–6420.Google Scholar
  37. 37.
    Murakami, M., I. Kudo, andK. Inoue. 1991. Eicosanoid generation from antigen-primed mast cells by extracellular mammalian 14-kDa group II phospholipase A2.FEBS Lett. 294:247–251.Google Scholar

Copyright information

© Plenum Publishing Corporation 1993

Authors and Affiliations

  • Mats Lindahl
    • 1
  • Christer Tagesson
    • 1
  1. 1.Departments of Clinical Chemistry and Occupational MedicineUniversity of LinköpingLinköpingSweden

Personalised recommendations